Safety and immunogenicity of early vaccination with two doses of tetravalent Measles-Mumps-Rubella-Varicella (MMRV) vaccine in healthy children from 9 months of age

Infection

Volumn 35, Issue 5, 2007, Pages 326-333

  Goh, P ^a   Lim, F S ^b   Han, H H ^c   Willems, P ^c  

^a SINGHEALTH POLYCLINICS   (Singapore)

^b NATIONAL HEALTHCARE GROUP POLYCLINICS   (Singapore)

^c GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CHICKENPOX MEASLES MUMPS RUBELLA VACCINE; CHICKENPOX VACCINE; MEASLES MUMPS RUBELLA VACCINE; VARICELLA ZOSTER VACCINE;

ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; AXILLA TEMPERATURE; CHICKENPOX; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FEVER; DRUG SAFETY; ERYTHEMA; FEVER; FOLLOW UP; HUMAN; IMMUNOGENICITY; INCIDENCE; MEASLES; MUMPS; PAIN; RANDOMIZED CONTROLLED TRIAL; RUBELLA; SEROCONVERSION; SWELLING; VACCINATION;

ANTIBODIES, VIRAL; CHICKENPOX VACCINE; ERYTHEMA; FEMALE; FEVER; HUMANS; INFANT; MALE; MEASLES-MUMPS-RUBELLA VACCINE; PAIN; VACCINES, COMBINED;

EID: 34848830796     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-007-6337-z     Document Type: Article

References (32)

1. World Health Organization Measles vaccines. Wkly Epidemiol Rec 2004; 79: 130-142.
2. World Health Organization: Measles: mortality reduction and regional elimination. Strategic plan: 2001-2005. World Health Organization 2001 (available at: http://www.who.int/vaccinesdocuments/DocsPDF01/ www573.pdf). Accessed 21 November 2006.
3. World Health Organization Progress toward elimination of measles and prevention of congenital rubella infection - European Region, 1990-2004. Wkly Epidemiol Rec 2005; 80: 65-76.
4. World Health Organization: Eliminating measles and rubella and preventing congenital rubella infection: WHO European Region strategic plan 2005-2010. World Health Organization 2005, updated reprint 2006 (available at: http://www.euro.who.int/document/E87772.pdf). Accessed 21 November 2006.
5. Robert Koch Institute Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: Juli 2006. Epidemiol Bull 2006; 30: 235-254.
6. Institut de Veille Sanitaire: Bulletin épidémiologique hebdomadaire Calendrier vaccinal 2005 et autres avis du conseil supérieur d'hygiène publique de France relatifs à la vaccination. 2005; 29-30: 142.
7. Prince Leopold Institute of Tropical Medicine: Travelling with children and babies. 2006 (available at: http://www.itg.be/itg/Uploads/MedServ/echildren. pdf). Accessed 21 November 2006.
8. Statens Serum Institut: Danish childhood vaccination programme: measles-mumps-rubella vaccination (MMR). (Available at: http://www.ssi.dk/ sw19336.asp). Accessed 21 November 2006.
9. Department of Health (United Kingdom): Measles, mumps and rubella. In: Immunisation against infectious disease (Green Book). 2006 (available at: http://www.dh.gov.uk/assetRoot/04/13/79/20/04137920.pdf). Accessed 21 November 2006.
10. Georgakopoulou T, Grylli C, Kalamara E, Katerelos P, Spala G, Panagiotopoulos T: Current measles outbreak in Greece. Euro Surveill 2006; 11: E060223.2.
11. Kuter B, Matthews H, Shinefield H, Black S, Dennehy P, Watson B, Reisinger K, Kim LL, Lupinacci L, Hartzel J, Chan I, Study Group for Varivax: Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr Infect Dis J 2004; 23: 132-137.
12. Arvin A, Gershon A: Control of varicella. Why is a two-dose schedule necessary? Pediatr Infect Dis J 2006; 25: 475-476.
13. Lopez AS, Guris D, Zimmerman L, Gladden L, Moore T, Haselow DT, Loparev VN, Schmid DS, Jumaan AO, Snow SL: One dose of varicella vaccine does not prevent school outbreaks: is it time for a second dose? Pediatrics 2006; 117: e1070-e1077.
14. Centers for Disease Control and Prevention: Advisory Committee on Immunization Practices (ACIP): provisional recommendations for the prevention of varicella. 2006 (available at: http://www.cdc.gov/nip/recs/provisional_recs/ default.htm). Accessed 21 November 2006.
15. Ross AM, Fleming DM: Chickenpox increasingly affects preschool children. Commun Dis Public Health 2000; 3: 213-215.
16. Kudesia G, Partridge S, Farrington CP, Soltanpoor N: Changes in age related seroprevalence of antibody to varicella zoster virus: impact on vaccine strategy. J Clin Pathol 2002; 55: 154-155.
17. Kilgore PE, Kruszon-Moran D, Seward JF, Jumaan A, Van Loon FP, Forghani B, McQuillan GM, Wharton M, Fehrs LJ, Cossen CK, Hadler SC: Varicella in Americans from NHANES III: implications for control through routine immunization. J Med Virol 2003; 70: 111-118.
18. Rentier B, Gershon AA and the Members of the European Working Group on Varicella (EUROVAR): Consensus: varicella vaccination of healthy children - a challenge for Europe. Pediatr Infect Dis J 2004; 23: 379-389.
19. Stuck B, Stehr K, Bock HL: Concomitant administration of varicella vaccine with combined measles, mumps, and rubella vaccine in healthy children aged 12 to 24 months of age. Asian Pac J Allergy Immunol 2002; 20: 113-120.
20. Wellington K, Goa KL: Measles, mumps, rubella vaccine (Priorix™; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella. Drugs 2003; 63: 2107-2126.
21. Vesikari T, Ohrling A, Baer M, Delem A, Bogaerts H, Andre FE: Evaluation of live attenuated varicella vaccine (Oka-RIT strain) and combined varicella and MMR vaccination in 13-17 month-old children. Acta Paediatr Scand 1991; 80: 1051-1057.
22. Watson BM, Laufer DS, Kuter BJ, Staehle B, White CJ, Starr SE: Safety and immunogenicity of a combined live attenuated measles, mumps, rubella, and varicella vaccine (MMR(II)V) in healthy children. J Infect Dis 1996; 173: 731-734.
23. White CJ, Stinson D, Staehle B, Cho I, Matthews H, Ngai A, Keller P, Eiden J, Kuter B: Measles, mumps, rubella, and varicella combination vaccine: safety and immunogenicity alone and in combination with other vaccines given to children. Measles, mumps, rubella, varicella vaccine study group. Clin Infect Dis 1997; 24: 925-931.
24. Nolan T, McIntyre P, Roberton D, Descamps D: Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine. Vaccine 2002; 21: 281-289.
25. Vesikari T, Baer M, Vandevoorde D: An early dose-finding study for an experimental MMRV vaccine (Abstract). In: 4th World Congress of The World Society of Paediatric Infectious Diseases, Warsaw, Poland 2005.
26. Shinefield H, Black S, Digilio L, Reisinger K, Blatter M, Gress JO, Brown ML, Eves KA, Klopfer SO, Schodel F, Kuter BJ: Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children. Pediatr Infect Dis J 2005; 24: 665-669.
27. Knuf M, Habermehl P, Zepp F, Mannhardt W, Kuttnig M, Muttonen P, Prieler A, Maurer H, Bisanz H, Tornieporth N, Descamps D, Willems P: Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children. Pediatr Infect Dis J 2006; 25: 12-18.
28. Peltola H, Heinonen OP: Frequency of true adverse reactions to measles-mumps-rubella vaccine. A double-blind placebo-controlled trial in twins. Lancet 1986; 1: 939-942.
29. Chen RT, Moses JM, Markowitz LE, Orenstein WA: Adverse events following measles-mumps-rubella and measles vaccinations in college students. Vaccine 1991; 9: 297-299.
30. Centers for Disease Control and Prevention: Measles. In: Atkinson W, Hamborsky J, McIntyre L, Wolfe S (eds.): Epidemiology and prevention of vaccine-preventable diseases (9th edn). Public Health Foundation, Washington DC 2006, pp 125-144.
31. Usonis V, Bakasenas V, Kaufhold A, Chitour K, Clemens R: Reactogenicity of a new live attenuated combined measles, mumps, rubella vaccine in healthy children. Pediatr Infect Dis J 1999; 18: 42-48.
32. Gans HA, Arvin AM, Galinus J, Logan L, DeHovitz R, Maldonado Y: Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. JAMA 1998; 280: 527-532.